Association between TNFAIP3 nonsynonymous single-nucleotide polymorphism rs2230926 and chronic hepatitis B virus infection in a Chinese Han population

Virology Journal

Zhengwen Liu¹  Qunying Han³  Zhihua Zhou³  Yi Lv¹  Xiaoyan Zeng²  Cuiling Yang³  Fang Li³  Qianqian Zhu³  Na Li³  Pingping Zhang³ 

[1] Institute of Advanced Surgical Technology and Engineering, Xi’an Jiaotong University, Xi’ an 710061, Shaanxi, China;Department of Laboratory Medicine, First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’ an 710061, Shaanxi, China;Department of Infectious Diseases, First Affiliated Hospital, School of Medicine, Xi’an Jiaotong University, Xi’ an 710061, Shaanxi Province, China

关键词: Clinical disease;    Susceptibility;    Polymorphism;    TNFAIP3;    Hepatitis B virus;   

Others  :  1148016
DOI  :  10.1186/s12985-015-0268-6

 received in 2015-01-06, accepted in 2015-02-18,  发布年份 2015

【 摘 要 】

Background

Single-nucleotide polymorphisms (SNPs) in tumor necrosis factor alpha-inducible protein 3 (TNFAIP3) gene have been linked to inflammatory, immunological and malignant diseases. Hepatitis B virus (HBV) infection is characterized by immunopathogenesis. This study investigated the association of rs2230926, a nonsynonymous SNP in TNFAIP3 gene, with chronic HBV infection.

Methods

Four hundred and fifty-five patients with chronic HBV infection with clinical diseases of chronic hepatitis (n = 183), liver cirrhosis (n = 167) and hepatocellular carcinoma (n = 105), 92 HBV infection resolvers and 171 healthy controls were included. All subjects were of Chinese Han ethnicity. Genotyping of rs2230926 was carried out by polymerase chain reaction-restriction fragment length polymorphism method.

Results

The gender and age between HBV patients, HBV infection resolvers and healthy controls had no statistical difference. The genotypes of rs2230926 in HBV patients, HBV infection resolvers and healthy controls are in Hardy-Weinberg equilibrium. The genotype and allele frequencies of TNFAIP3 rs2230926 polymorphism between HBV patients, HBV infection resolvers and healthy controls had no significant difference. The genotype and allele frequencies of TNFAIP3 rs2230926 polymorphism between HBV patients with chronic hepatitis, liver cirrhosis and hepatocellular carcinoma also showed no significant difference.

Conclusions

The TNFAIP3 rs2230926 polymorphism is not suggested to be associated with the susceptibility of chronic HBV infection or the progression of HBV-related diseases in this study. Replicative studies and studies in large control and HBV patient populations of different ethnicity by genotyping more polymorphisms in TNFAIP3 gene are needed.

【 授权许可】

   
2015 Zhang et al.; licensee BioMed Central.

【 参考文献 】

• [1]Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP: Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006, 28:112-25.
• [2]Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al.: Natural history and prognostic factors for chronic hepatitis type B. Gut 1991, 32:294-8.
• [3]Locarnini S: Molecular virology of hepatitis B virus. Semin Liver Dis 2004, 24(Suppl 1):3-10.
• [4]Kakimi K, Guidotti LG, Koezuka Y, Chisari FV: Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000, 192:921-30.
• [5]Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, et al.: Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Gut 2009, 58:974-82.
• [6]TrehanPati N, Geffers R, Sukriti , Hissar S, Riese P, Toepfer T, et al.: Gene expression signatures of peripheral CD4+ T cells clearly discriminate between patients with acute and chronic hepatitis B infection. Hepatology 2009, 49:781-90.
• [7]Das A, Hoare M, Davies N, Lopes AR, Dunn C, Kennedy PT, et al.: Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 2008, 205:2111-24.
• [8]Op den Brouw ML, Binda RS, van Roosmalen MH, Protzer U, Janssen HL, van der Molen RG, et al.: Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology 2009, 126:280-9.
• [9]Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, et al.: Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005, 41:771-8.
• [10]Yi JS, Cox MA, Zajac AJ: T-cell exhaustion: characteristics, causes and conversion. Immunology 2010, 129:474-81.
• [11]Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, et al.: Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology 2010, 138:682-93. 693 e681-684
• [12]Schurich A, Khanna P, Lopes AR, Han KJ, Peppa D, Micco L, et al.: Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology 2011, 53:1494-503.
• [13]Zhang G, Liu Z, Duan S, Han Q, Li Z, Lv Y, et al.: Association of polymorphisms of programmed cell death-1 gene with chronic hepatitis B virus infection. Hum Immunol 2010, 71:1209-13.
• [14]Duan S, Zhang G, Han Q, Li Z, Liu Z, Chen J, et al.: CTLA-4 exon 1 +49 polymorphism alone and in a haplotype with −318 promoter polymorphism may confer susceptibility to chronic HBV infection in Chinese Han patients. Mol Biol Rep 2011, 38:5125-32.
• [15]Li Z, Liu Z, Zhang G, Han Q, Li N, Zhu Q, et al.: TIM3 gene polymorphisms in patients with chronic hepatitis B virus infection: impact on disease susceptibility and hepatocellular carcinoma traits. Tissue Antigens 2012, 80:151-7.
• [16]Jaattela M, Mouritzen H, Elling F, Bastholm L: A20 zinc finger protein inhibits TNF and IL-1 signaling. J Immunol 1996, 156:1166-73.
• [17]Lee EG, Boone DL, Chai S, Libby SL, Chien M, Lodolce JP, et al.: Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000, 289:2350-4.
• [18]Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, et al.: The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004, 5:1052-60.
• [19]Hitotsumatsu O, Ahmad RC, Tavares R, Wang M, Philpott D, Turer EE, et al.: The ubiquitin-editing enzyme A20 restricts nucleotide-binding oligomerization domain containing 2-triggered signals. Immunity 2008, 28:381-90.
• [20]Ma A, Malynn BA: A20: linking a complex regulator of ubiquitylation to immunity and human disease. Nat Rev Immunol 2012, 12:774-85.
• [21]Kawasaki A, Ito I, Ito S, Hayashi T, Goto D, Matsumoto I, et al.: Association of TNFAIP3 polymorphism with susceptibility to systemic lupus erythematosus in a Japanese population. J Biomed Biotechnol 2010, 2010:207578.
• [22]Vereecke L, Beyaert R, van Loo G: The ubiquitin-editing enzyme A20 (TNFAIP3) is a central regulator of immunopathology. Trends Immunol 2009, 30:383-91.
• [23]Song GG, Bae SC, Lee YH: Pathway analysis of genome-wide association studies on rheumatoid arthritis. Clin Exp Rheumatol 2013, 31:566-74.
• [24]Musone SL, Taylor KE, Lu TT, Nititham J, Ferreira RC, Ortmann W, et al.: Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 2008, 40:1062-4.
• [25]Lee YH, Song GG: Associations between TNFAIP3 gene polymorphisms and systemic lupus erythematosus: a meta-analysis. Genet Test Mol Biomarkers 2012, 16:1105-10.
• [26]Shimane K, Kochi Y, Horita T, Ikari K, Amano H, Hirakata M, et al.: The association of a nonsynonymous single-nucleotide polymorphism in TNFAIP3 with systemic lupus erythematosus and rheumatoid arthritis in the Japanese population. Arthritis Rheum 2010, 62:574-9.
• [27]Cai LQ, Wang ZX, Lu WS, Han JW, Sun LD, Du WH, et al.: A single-nucleotide polymorphism of the TNFAIP3 gene is associated with systemic lupus erythematosus in Chinese Han population. Mol Biol Rep 2010, 37:389-94.
• [28]Cen H, Zhou M, Leng RX, Wang W, Feng CC, Li BZ, et al.: Genetic interaction between genes involved in NF-kappaB signaling pathway in systemic lupus erythematosus. Mol Immunol 2013, 56:643-8.
• [29]Fan Y, Tao JH, Zhang LP, Li LH, Ye DQ: The association between BANK1 and TNFAIP3 gene polymorphisms and systemic lupus erythematosus: a meta-analysis. Int J Immunogenet 2011, 38:151-9.
• [30]Musone SL, Taylor KE, Nititham J, Chu C, Poon A, Liao W, et al.: Sequencing of TNFAIP3 and association of variants with multiple autoimmune diseases. Genes Immun 2011, 12:176-82.
• [31]Lee YH, Bae SC, Choi SJ, Ji JD, Song GG: Associations between TNFAIP3 gene polymorphisms and rheumatoid arthritis: a meta-analysis. Inflamm Res 2012, 61:635-41.
• [32]Zagoriti Z, Georgitsi M, Giannakopoulou O, Ntellos F, Tzartos SJ, Patrinos GP, et al.: Genetics of myasthenia gravis: a case–control association study in the Hellenic population. Clin Dev Immunol 2012, 2012:484919.
• [33]Shi YY, He L: SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005, 15:97-8.
• [34]Zhang X, Li W, Zhao L, Jiang L, Guo Y, Zhang J, et al.: Single nucleotide polymorphisms in TNFAIP3 were associated with the risks of rheumatoid arthritis in northern Chinese Han population. BMC Med Genet 2014, 15:56. BioMed Central Full Text
• [35]Kim SK, Choe JY, Bae J, Chae SC, Park DJ, Kwak SG, et al.: TNFAIP3 gene polymorphisms associated with differential susceptibility to rheumatoid arthritis and systemic lupus erythematosus in the Korean population. Rheumatology (Oxford) 2014, 53:1009-13.
• [36]Adrianto I, Wen F, Templeton A, Wiley G, King JB, Lessard CJ, et al.: Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet 2011, 43:253-8.
• [37]Wang S, Wen F, Wiley GB, Kinter MT, Gaffney PM: An enhancer element harboring variants associated with systemic lupus erythematosus engages the TNFAIP3 promoter to influence A20 expression. PLoS Genet 2013, 9:e1003750.
• [38]Biermer M, Puro R, Schneider RJ: Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB. J Virol 2003, 77:4033-42.
• [39]Satake S, Nagaki M, Kimura K, Moriwaki H: Inhibition of nuclear factor-kappa B induces inflammatory cell migration and exacerbates severe liver injury in hepatitis B virus transgenic mice. Hepatol Res 2007, 37:524-30.
• [40]Clippinger AJ, Gearhart TL, Bouchard MJ: Hepatitis B virus X protein modulates apoptosis in primary rat hepatocytes by regulating both NF-kappaB and the mitochondrial permeability transition pore. J Virol 2009, 83:4718-31.